Search Results - "Soichiro Saikawa"

Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake by Kaji, Kosuke, Nishimura, Norihisa, Seki, Kenichiro, Sato, Shinya, Saikawa, Soichiro, Nakanishi, Keisuke, Furukawa, Masanori, Kawaratani, Hideto, Kitade, Mitsuteru, Moriya, Kei, Namisaki, Tadashi, Yoshiji, Hitoshi

“…Sodium‐glucose cotransporter 2 inhibitors (SGLT2‐Is) comprise a new class of antidiabetic agents that inhibit glucose reabsorption in the renal proximal…”
Get full text

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity by Kaji, Kosuke, Takaya, Hiroaki, Saikawa, Soichiro, Furukawa, Masanori, Sato, Shinya, Kawaratani, Hideto, Kitade, Mitsuteru, Moriya, Kei, Namisaki, Tadashi, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi

“…AIM To determine the efficacy of rifaximin for hepatic encephalopathy(HE) with the linkage of gut microbiome in decompensated cirrhotic patients.METHODS Twenty…”
Get full text

Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis by Furukawa, Masanori, Moriya, Kei, Nakayama, Jiro, Inoue, Takako, Momoda, Rie, Kawaratani, Hideto, Namisaki, Tadashi, Sato, Shinya, Douhara, Akitoshi, Kaji, Kosuke, Kitade, Mitsuteru, Shimozato, Naotaka, Sawada, Yasuhiko, Saikawa, Soichiro, Takaya, Hiroaki, Kitagawa, Koh, Akahane, Takemi, Mitoro, Akira, Yamao, Junichi, Tanaka, Yasuhito, Yoshiji, Hitoshi

“…Aim Although some relationships between gut microbiota and liver diseases have been reported, it remains uncertain whether changes in gut microbiota owing to…”
Get full text

Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells by Kitagawa, Koh, Moriya, Kei, Kaji, Kosuke, Saikawa, Soichiro, Sato, Shinya, Nishimura, Norihisa, Namisaki, Tadashi, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi

“…Cholangiocarcinoma (CCA) is associated with high mortality rates because of its resistance to conventional gemcitabine-based chemotherapy…”
Get full text

Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein by Saikawa, Soichiro, Kaji, Kosuke, Nishimura, Norihisa, Seki, Kenichiro, Sato, Shinya, Nakanishi, Keisuke, Kitagawa, Koh, Kawaratani, Hideto, Kitade, Mitsuteru, Moriya, Kei, Namisaki, Tadashi, Mitoro, Akira, Yoshiji, Hitoshi

“…Cholangiocarcinoma (CCA) is a destructive malignancy with limited responsiveness to conventional chemotherapy. Although angiotensin receptor blockers (ARBs)…”
Get full text

Combining probiotics and an angiotensin‐II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non‐alcoholic steatohepatitis by Sawada, Yasuhiko, Kawaratani, Hideto, Kubo, Takuya, Fujinaga, Yukihisa, Furukawa, Masanori, Saikawa, Soichiro, Sato, Shinya, Seki, Kenichiro, Takaya, Hiroaki, Okura, Yasushi, Kaji, Kosuke, Shimozato, Naotaka, Mashitani, Tsuyoshi, Kitade, Mitsuteru, Moriya, Kei, Namisaki, Tadashi, Akahane, Takemi, Mitoro, Akira, Yamao, Junichi, Yoshiji, Hitoshi

“…Aim Intestinal endotoxin is important for the progression of non‐alcoholic steatohepatitis (NASH). Circulating endotoxin levels are elevated in most animal…”
Get full text

Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model by Nakanishi, Keisuke, Kaji, Kosuke, Kitade, Mitsuteru, Kubo, Takuya, Furukawa, Masanori, Saikawa, Soichiro, Shimozato, Naotaka, Sato, Shinya, Seki, Kenichiro, Kawaratani, Hideto, Moriya, Kei, Namisaki, Tadashi, Yoshiji, Hitoshi

“…Various rodent models have been proposed for basic research; however, the pathogenesis of human nonalcoholic steatohepatitis (NASH) is difficult to closely…”
Get full text

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma by Takaya, Hiroaki, Namisaki, Tadashi, Kitade, Mitsuteru, Kaji, Kosuke, Nakanishi, Keisuke, Tsuji, Yuki, Shimozato, Naotaka, Moriya, Kei, Seki, Kenichiro, Sawada, Yasuhiko, Saikawa, Soichiro, Sato, Shinya, Kawaratani, Hideto, Akahane, Takemi, Noguchi, Ryuichi, Matsumoto, Masanori, Yoshiji, Hitoshi

“…To investigate the von Willebrand factor to ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma (HCC) in cirrhosis. Serum…”
Get full text

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis by Ozutsumi, Takahiro, Namisaki, Tadashi, Shimozato, Naotaka, Kaji, Kosuke, Tsuji, Yuki, Kaya, Daisuke, Fujinaga, Yukihisa, Furukawa, Masanori, Nakanishi, Keisuke, Sato, Shinya, Sawada, Yasuhiko, Saikawa, Soichiro, Kitagawa, Koh, Takaya, Hiroaki, Kawaratani, Hideto, Kitade, Mitsuteru, Moriya, Kei, Noguchi, Ryuichi, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi

“…Hepatocellular carcinoma (HCC) is the strongest independent predictor of mortality in non-alcoholic steatohepatitis (NASH)-related cirrhosis. The effects and…”
Get full text

Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis by Shimozato, Naotaka, Namisaki, Tadashi, Kaji, Kosuke, Kitade, Mitsuteru, Okura, Yasushi, Sato, Shinya, Moriya, Kei, Seki, Kenichiro, Kawaratani, Hideto, Takaya, Hiroaki, Sawada, Yasuhiko, Saikawa, Soichiro, Nakanishi, Keisuke, Furukawa, Masanori, Fujinaga, Yukihisa, Kubo, Takuya, Asada, Kiyoshi, Kitagawa, Koh, Tsuji, Yuki, Kaya, Daisuke, Ozutsumi, Takahiro, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi

“…Aim Non‐alcoholic steatohepatitis (NASH) has a broad clinicopathological spectrum (inflammation to severe fibrosis). The farnesoid X receptor agonist…”
Get full text

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients by Kaji, Kosuke, Saikawa, Soichiro, Takaya, Hiroaki, Fujinaga, Yukihisa, Furukawa, Masanori, Kitagawa, Koh, Ozutsumi, Takahiro, Kaya, Daisuke, Tsuji, Yuki, Sawada, Yasuhiko, Kawaratani, Hideto, Moriya, Kei, Namisaki, Tadashi, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi

“…Rifaximin is a poorly absorbable antibiotic against hepatic encephalopathy (HE). This observational study aimed to elucidate the effect of rifaximin on…”
Get full text

Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor by Furukawa, Masanori, Mitoro, Akira, Ozutumi, Takahiro, Fujinaga, Yukihisa, Nakanishi, Keisuke, Kitagawa, Koh, Saikawa, Soichiro, Sato, Sinya, Sawada, Yasuhiko, Takaya, Hiroaki, Kaji, Kosuke, Kawaratani, Hideto, Namisaki, Tadashi, Moriya, Kei, Akahane, Takemi, Yamao, Junichi, Yoshiji, Hitoshi

“…Endoscopic resection (ER) for superficial non-ampullary duodenal epithelial tumors (SNADETs) is challenging. Conventional endoscopic mucosal resection (CEMR)…”
Get full text

Combined treatment with dipeptidyl peptidase‐4 inhibitor (sitagliptin) and angiotensin‐II type 1 receptor blocker (losartan) suppresses progression in a non‐diabetic rat model of steatohepatitis by Okura, Yasushi, Namisaki, Tadashi, Moriya, Kei, Kitade, Mitsuteru, Takeda, Kosuke, Kaji, Kosuke, Noguchi, Ryuichi, Nishimura, Norihisa, Seki, Kenichiro, Kawaratani, Hideto, Takaya, Hiroaki, Sato, Shinya, Sawada, Yasuhiko, Shimozato, Naotaka, Furukawa, Masanori, Nakanishi, Keisuke, Saikawa, Soichiro, Kubo, Takuya, Asada, Kiyoshi, Yoshiji, Hitoshi

“…Aim Dipeptidyl peptidase‐4 (DPP4) inhibitors (DPP4‐I) are oral glucose‐lowering drugs for type 2 diabetes mellitus. Previously, we reported that DPP4‐I…”
Get full text

Blocking development of liver fibrosis augments hepatic progenitor cell‐derived liver regeneration in a mouse chronic liver injury model by Kitade, Mitsuteru, Kaji, Kosuke, Nishimura, Norihisa, Seki, Kenichiro, Nakanishi, Keisuke, Tsuji, Yuki, Sato, Shinya, Saikawa, Soichiro, Takaya, Hiroaki, Kawaratani, Hideto, Namisaki, Tadashi, Moriya, Kei, Mitoro, Akira, Yoshiji, Hitoshi

“…Aim The roles of hepatic progenitor cells (HPCs) in regeneration of a diseased liver are unclear. Hepatic stellate cells (HSCs) contribute to liver fibrosis…”
Get full text

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients by Moriya, Kei, Namisaki, Tadashi, Sato, Shinya, Furukawa, Masanori, Douhara, Akitoshi, Kawaratani, Hideto, Kaji, Kosuke, Shimozato, Naotaka, Sawada, Yasuhiko, Saikawa, Soichiro, Takaya, Hiroaki, Kitagawa, Koh, Akahane, Takemi, Mitoro, Akira, Yamao, Junichi, Yoshiji, Hitoshi

“…We previously reported the comparable efficacy of bi-monthly hepatic arterial infusion chemotherapy (B-HAIC) to that of sorafenib chemotherapy for the…”
Get full text

Thyroid‐stimulating hormone is an independent risk factor of non‐alcoholic fatty liver disease by Tahara, Kazuki, Akahane, Takemi, Namisaki, Tadashi, Moriya, Kei, Kawaratani, Hideto, Kaji, Kosuke, Takaya, Hiroaki, Sawada, Yasuhiko, Shimozato, Naotaka, Sato, Shinya, Saikawa, Soichiro, Nakanishi, Keisuke, Kubo, Takuya, Fujinaga, Yukihisa, Furukawa, Masanori, Kitagawa, Koh, Ozutsumi, Takahiro, Tsuji, Yuuki, Kaya, Daisuke, Ogawa, Hiroyuki, Takagi, Hirotetsu, Ishida, Koji, Mitoro, Akira, Yoshiji, Hitoshi

“…Background and Aim Hypothyroidism might play a crucial role in the pathogenesis of non‐alcoholic fatty liver disease (NAFLD). The association of subclinical…”
Get full text

Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study by Nakanishi, Keisuke, Namisaki, Tadashi, Mashitani, Tsuyoshi, Kaji, Kosuke, Ozaki, Kuniaki, Saikawa, Soichiro, Sato, Shinya, Inoue, Takashi, Sawada, Yasuhiko, Kitagawa, Kou, Takaya, Hiroaki, Shimozato, Naotaka, Kawaratani, Hideto, Moriya, Kei, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi

“…Cirrhosis patients often have abnormal glucose metabolism. We investigated the effects of a late-evening snack (LES) with branched-chain amino acid-enriched…”
Get full text

Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis by Okura, Yasushi, Namisaki, Tadashi, Sato, Shinya, Moriya, Kei, Akahane, Takemi, Kitade, Mitsuteru, Kawaratani, Hideto, Kaji, Kosuke, Takaya, Hiroaki, Sawada, Yasuhiko, Shimozato, Naotaka, Seki, Kenichiro, Saikawa, Soichiro, Nakanishi, Keisuke, Furukawa, Masanori, Fujinaga, Yukihisa, Kubo, Takuya, Kaya, Daisuke, Tsuji, Yuki, Ozutsumi, Takahiro, Kitagawa, Koh, Mashitani, Tsuyoshi, Ogawa, Hiroyuki, Ishida, Koji, Mitoro, Akira, Yamao, Junichi, Yoshiji, Hitoshi

“…Aim Proton pump inhibitors (PPIs) are frequently prescribed in patients with cirrhosis, but this therapy entails potential complications. We aimed to…”
Get full text

Identification of clinical risk factors for histological progression of primary biliary cholangitis by Fujinaga, Yukihisa, Namisaki, Tadashi, Moriya, Kei, Kitade, Mitsuteru, Kawaratani, Hideto, Shimozato, Naotaka, Kaji, Kosuke, Takaya, Hiroaki, Sawada, Yasuhiko, Seki, Kenichiro, Akahane, Takemi, Okura, Yasushi, Sato, Shinya, Saikawa, Soichiro, Nakanishi, Keisuke, Kubo, Takuya, Furukawa, Masanori, Kitagawa, Koh, Ozutsumi, Takahiro, Tsuji, Yuki, Kaya, Daisuke, Mashitani, Tsuyoshi, Ishida, Koji, Ogawa, Hiroyuki, Takagi, Hirotetsu, Noguchi, Ryuichi, Mitoro, Akira, Yamao, Junichi, Yoshiji, Hitoshi

“…Aim To identify laboratory predictors of histological progression (HP) of primary biliary cholangitis (PBC). Methods Sequential biopsies were carried out on 35…”
Get full text

Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients by Namisaki, Tadashi, Moriya, Kei, Kitade, Mitsuteru, Kawaratani, Hideto, Takeda, Kosuke, Okura, Yasushi, Takaya, Hiroaki, Nishimura, Norihisa, Seki, Kenichiro, Kaji, Kosuke, Sato, Shinya, Sawada, Yasuhiko, Yamao, Junichi, Mitoro, Akira, Uejima, Masakazu, Mashitani, Tsuyoshi, Shimozato, Naotaka, Nakanishi, Keisuke, Furukawa, Masanori, Saikawa, Soichiro, Kubo, Takuya, Yoshiji, Hitoshi

“…BACKGROUNDInadequate response to ursodeoxycholic acid (UDCA) is associated with unfavorable outcomes in patients with primary biliary cholangitis (PBC). We…”
Get full text